Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer Patients
Julienne E. Bower(APLA Health), Catherine M. Crespi(University of California, Los Angeles), Judith Carroll(University of California, Los Angeles), Laura Petersen(APLA Health), Kate R. Kuhlman(Salk Institute for Biological Studies), Arash Asher(Cedars-Sinai Medical Center), Sara A. Hurvitz(University of Washington), Deborah Garet(University of California, Los Angeles), Michael R. Irwin(University of California, Los Angeles), Patricia A. Ganz(Los Angeles County Department of Public Health), Steve W. Cole(APLA Health)
Cited by 41
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
|Journal of Clinical Oncology|2015|1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k